Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation

J. P. Clancy, Steven M. Rowe, Frank J. Accurso, Moira L. Aitken, Raouf S. Amin, Melissa A. Ashlock, Manfred Ballmann, Michael P. Boyle, Inez Bronsveld, Preston W. Campbell, Kris De Boeck, Scott H. Donaldson, Henry L. Dorkin, Jordan M. Dunitz, Peter R. Durie, Manu Jain, Anissa Leonard, Karen S. McCoy, Richard B. Moss, Joseph M. PilewskiDaniel B. Rosenbluth, Ronald C. Rubenstein, Michael S. Schechter, Martyn Botfield, Claudia L. Ordoñez, George T. Spencer-Green, Laurent Vernillet, Steve Wisseh, Karl Yen, Michael W. Konstan

Research output: Contribution to journal › Article › peer-review

407 Scopus citations

Fingerprint

Dive into the research topics of 'Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation'. Together they form a unique fingerprint.

Medicine & Life Sciences